MULTICENTER, STUDY OF ARIMOCLOMOL IN AMYOTROPHIC LATERAL SCLEROSIS (ALS)

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的主要目的是评估Arimoclomol在三种剂量下与安慰剂相比在80名ALS患者中治疗12周的安全性和耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to assess the safety and tolerability of Arimoclomol at three dosages as compared with placebo over 12 weeks of treatment in 80 patients with ALS.